Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate in Binge-Eating Disorder
NCT00511940Phase 3Completed
- Sponsor
- Lindner Center of HOPE
- Start
- Apr 2007
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) comparing Acamprosate with Placebo (2 arms). Primary endpoint: Change in weekly binge frequency at 10 weeks. Started Apr 2007; status: completed.
02
Drugs
acamprosate
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT00511940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511940.